Montelukast Treatment for Adults With Anterior ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

What this Trial Is About

Acute myocardial infarction AMI, especially ST-segment elevation myocardial infarction STEMI, remains a leading cause of death worldwide despite advances in reperfusion treatments. Mortality rates remain significant even when primary percutaneous coronary intervention pPCI is timely administered, and many survivors develop heart failure. This trial explores the role of leukotriene C4 LTC4 in myocardial ischemia-reperfusion injury IRI and investigates montelukast, a leukotriene receptor antagonist, as a potential therapy to reduce heart damage and improve outcomes in STEMI patients undergoing pPCI. Participants will be randomly assigned to receive either montelukast at a dose of 10 mg daily or a placebo for three months following enrollment. The study is triple-masked, meaning that participants, care providers, and researchers do not know which treatment is given. The treatment period aims to assess the effects of montelukast on heart protection after the acute myocardial event. Throughout the study, participants will be monitored for changes in left ventricular remodeling over 24 weeks from enrollment to the end of treatment. The trial includes assessments of heart function and structure, with cardiac magnetic resonance imaging used to evaluate outcomes. Safety and tolerance of the treatment will also be observed, and patient progress will be followed up during the 6-month study period to measure cardiac function and remodeling improvements.

Efficacy of Montelukast on STEMl Patients